Company news
Caliway Biopharmaceuticals Co Ltd news in 2025
Caliway Biopharmaceuticals Co Ltd's news releases, calls and decks from 2025, newest first.
Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies
December 24, 2025
Caliway Met Dual Milestones with MSCI Global Standard Index Inclusion, and Health Canada has Approved the Phase 3 SUPREME-01 Study
August 12, 2025
Caliway Announces FDA Clearance of IND Application for CBL-514 to Proceed with SUPREME-01, the First Global Pivotal Phase 3 Study for Reducing Abdominal Subcutaneous Fat
July 28, 2025
Caliway Announces Successful EOP2 Meeting with the FDA for CBL-514 in Reduction of Abdominal Subcutaneous Fat
May 14, 2025
Caliway's CBL-514 Phase 2 Study (CBL-0202) Accepted for Publication in the Aesthetic Surgery Journal
March 12, 2025
Caliway Announces CBL-514 Second Phase 2b Study Results (CBL-0205) Met Endpoints
February 8, 2025